China Meheco(SH:600056) Zhong Zheng Wang·2025-08-11 08:45Core Viewpoint - Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (referred to as "Zhonghui Biotech") officially listed on the Hong Kong Stock Exchange, becoming the 9th local listed company in the China Medical City located in Taizhou [1] Company Overview - Zhonghui Biotech focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological methods [1] - The company has launched a subunit influenza vaccine product and has obtained multiple clinical approval documents for new vaccine drugs, currently conducting clinical trials and new drug applications (NDA) [1] Key Products - One of the core products is the first domestic quadrivalent subunit influenza vaccine, Hui Er Kang Xin, which has significant upgrades over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and low risk of adverse reactions, making it more effective against influenza viruses [1] - Another core product under development is a lyophilized human rabies vaccine (human diploid cells), which is developed using human diploid cells, providing enhanced safety and is expected to be a good alternative to the mainstream Vero cell rabies vaccine [1] - The company completed Phase I clinical trials for the rabies vaccine in October 2024 and plans to start Phase III clinical trials in the third quarter of this year [1] Future Plans - The chairman and general manager of Zhonghui Biotech, An Youcai, stated that the listing is not the end but a new beginning, aiming to deepen the innovation vaccine field, accelerate the clinical and registration processes of core products, expand production and commercialization capabilities, and explore international markets to contribute to global public health [1]